Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis

Jianxun Wang; Chang Feng; Yuqi He; Wei Ding; Jianqiu Sheng; Muhammad Arshad; Xiaojie Zhang; Peifeng Li

doi:10.18632/oncotarget.4392

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis

Jianxun Wang, Chang Feng, Yuqi He, Wei Ding, Jianqiu Sheng, Muhammad Arshad, Xiaojie Zhang and Peifeng Li _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:27700-27713. https://doi.org/10.18632/oncotarget.4392

Metrics: PDF 1509 views | HTML 1895 views | ?

Abstract

Jianxun Wang1,*, Chang Feng2,*, Yuqi He3,*, Wei Ding4, Jianqiu Sheng3, Muhammad Arshad2, Xiaojie Zhang2, Peifeng Li1

1Institute for Translational Medicine, Medical College of Qingdao University, Qingdao, 266021, China

2National Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China

3Department of Gastroenterology, Beijing Military General Hospital, Beijing, 100700, China

4Affiliated Hospital, Medical College of Qingdao University, Qingdao, 266003, China

*These authors have contributed equally to this work

Correspondence to:

Peifeng Li, e-mail: [email protected]

Jianxun Wang, e-mail: [email protected]

Keywords: chemotherapy resistance, ARC, CK2, apoptosis, doxorubicin

Received: February 05, 2015 Accepted: June 17, 2015 Published: June 27, 2015

ABSTRACT

The development of cancer resistance to chemotherapy is the major obstacle to cancer therapy. Here, we identified that the phosphorylation of apoptosis repressor with caspase recruitment domain (ARC) at threonine 149 was essential to inhibit doxorubicin (DOX) induced apoptosis and mitochondrial fission in cancer cells. Our further study showed that casein kinase II (CK2) inhibitors could decrease the phosphorylation levels of ARC and make cancer cells sensitive to undergoing apoptosis. Furthermore, CK2α and CK2α', catalytic subunits of CK2, were observed to translocate into nuclear in cancer cells with the treatment of DOX. Finally, the synergistically therapeutic effect by combining DOX and CK2 inhibitor was confirmed in tumor xenograft model. Taken together, our results revealed that CK2-mediated phosphorylation of ARC contributed to chemotherapy resistance by inhibiting DOX induced apoptosis and combining DOX with CK2 inhibitor could induce apoptosis of cancer cells synergistically by down-regulating the phosphorylation of ARC. Therefore, development of new therapeutic strategies based on ARC and CK2, is promising for overcoming cancer resistance to chemotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4392

Publication Alerts

Research Papers:

Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis

Abstract